Abstract
Mavacamten (Camzyos (TM)) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
